The EMA has announced organizational adjustments and important strategic amendments of its corporate management structure that will result in a leaner, more streamlined architecture and improved administrative support. Building on the 2013/2014 reorganization of the agency, the changes fine-tune the re-engineered organizational model to further improve efficiency and effectiveness of EMA’s operations. All changes will come into effect on September 1, 2016.
“We want to do more with the resources we have by designing the Agency’s structures and processes around the lifespan of medicines,” said EMA’s Executive Director Guido Rasi. “With the changes announced today we are fine-tuning our operating model which has proven successful over the past two years and strengthening the efficiency of our administration.”
The main changes include:
Interactions between stakeholders and the agency will not be affected by these changes.